NFKB1 and diabetic kidney disease: APS was proven to inhibit the expression of inflammatory factors and alleviate diabetic nephropathy by inhibiting the NF-κB signaling pathway in streptozotocin-induced diabetic nephropathy rats [113,114] (Figure 310).